Scarica l'app Stockscreener
42.24
0.23%
0.095
Dopo l'orario di chiusura:
42.83
0.585
+1.38%
Precedente Chiudi:
$42.15
Aprire:
$42.34
Volume 24 ore:
887.85K
Relative Volume:
0.53
Capitalizzazione di mercato:
$6.72B
Reddito:
$705.14M
Utile/perdita netta:
$-453.90M
Rapporto P/E:
-13.90
EPS:
-3.04
Flusso di cassa netto:
$-551.29M
1 W Prestazione:
+1.16%
1M Prestazione:
+5.61%
6M Prestazione:
+21.57%
1 anno Prestazione:
-18.54%
Intervallo 1D:
$41.60
$42.55
Intervallo di 1 settimana:
$41.25
$42.81
Portata 52W:
$23.95
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Confronta IONS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
42.24 | 6.71B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Neutral |
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha
Is Ionis Pharmaceuticals Inc. a good long term investmentBreakthrough capital growth - Autocar Professional
TRYNGOLZA Receives EU CHMP Approval Recommendation for Rare Disease FCS Treatment | IONS Stock News - Stock Titan
Ionis Pharmaceuticals Inc. Stock Analysis and ForecastRemarkably fast returns - jammulinksnews.com
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Ionis Pharmaceuticals founder Stanley Crooke on the fight against rare diseases - MSN
What analysts say about Ionis Pharmaceuticals Inc. stockRapid portfolio appreciation - Autocar Professional
What drives Ionis Pharmaceuticals Inc. stock priceHigh-profit trading signals - jammulinksnews.com
Lou Gehrig’s Disease Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corpo - Barchart.com
Pinning Down Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) P/S Is Difficult Right Now - 富途牛牛
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 - GlobeNewswire Inc.
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
Ionis HAE drug shows strong results in switch study - Investing.com Australia
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice - Yahoo Finance
Global Motor Neuron Disease Treatment Market to Exhibit Substantial Growth at a CAGR of ~6% by 2032 | DelveInsight - Yahoo Finance
Hutchinson-Gilford Progeria Syndrome Market Driven - openPR.com
(IONS) Technical Data - news.stocktradersdaily.com
Ionis Pharmaceuticals to Host Q2 2025 Earnings Webcast on July 30th - AInvest
Ionis to hold second quarter 2025 financial results webcast - Business Wire
Ionis To Hold Second Quarter 2025 Financial Results Webcast - Barchart.com
Ionis Pharma CEO Monia sells $48,416 in stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals CEO Monia Brett Sells 1160 Shares at $41.74 - AInvest
Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Spinocerebellar Ataxias Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc, Biohaven Pharma - Barchart.com
Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT - Insider Monkey
11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds - Insider Monkey
Ionis Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress - Investing.com
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire - MSN
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last? - MSN
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN
Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross? - Zacks Investment Research
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Climb 28% But Its Business Is Yet to Catch Up - simplywall.st
Ionis Pharmaceuticals Surges Amid Promising SMA Treatment Progress - StocksToTrade
Ionis Pharmaceuticals Advances as Barclays Upgrades Stock - timothysykes.com
Ionis Pharmaceuticals shares surge 8.89% intraday after Barclays analyst upgrades rating to 'Overweight'. - AInvest
10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know - Nasdaq
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ionis Pharmaceuticals Inc Azioni (IONS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| YANG MICHAEL J. | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
6,010 |
| WENDER JOSEPH H | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
136,835 |
| PARSHALL B LYNNE | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
91,344 |
| HERMAN JOAN E | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
46,086 |
| Hayden Michael R | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
54,298 |
| Diaz Allene M. | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
19,795 |
| BERTHELSEN SPENCER R | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
156,013 |
| Monia Brett P | Chief Executive Officer |
Jul 11 '25 |
Sale |
41.74 |
1,160 |
48,416 |
179,820 |
| Hayden Michael R | Director |
May 01 '25 |
Buy |
31.86 |
15,000 |
477,900 |
50,219 |
| Birchler Brian | EVP, Corp and Development Ops |
Apr 15 '25 |
Option Exercise |
0.00 |
1,875 |
0 |
57,340 |
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):